Epidemiology of chronic myeloid leukaemia: an update
M Höglund, F Sandin, B Simonsson - Annals of hematology, 2015 - Springer
National and regional population-based registries are, provided diagnostic accuracy and full
coverage of the target population, indispensible tools for epidemiological research. Chronic …
coverage of the target population, indispensible tools for epidemiological research. Chronic …
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini… - Journal of the …, 2011 - academic.oup.com
Background Imatinib slows development of chronic myeloid leukemia (CML). However,
available information on morbidity and mortality is largely based on sponsored trials …
available information on morbidity and mortality is largely based on sponsored trials …
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
R Piazza, S Valletta, N Winkelmann, S Redaelli… - Nature …, 2013 - nature.com
Atypical chronic myeloid leukemia (aCML) shares clinical and laboratory features with CML,
but it lacks the BCR-ABL1 fusion. We performed exome sequencing of eight aCMLs and …
but it lacks the BCR-ABL1 fusion. We performed exome sequencing of eight aCMLs and …
The role of bosutinib in the treatment of chronic myeloid leukemia
The availability of several BCR-ABL1 tyrosine kinase inhibitor (TKI) options means
physicians and patients can select the most appropriate treatment for a patient with chronic …
physicians and patients can select the most appropriate treatment for a patient with chronic …
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study
H Frederiksen, DK Farkas… - Blood, The Journal …, 2011 - ashpublications.org
Patients with chronic myeloproliferative neoplasms, including essential thrombocythemia
(ET), polycythemia vera (PV), and chronic myeloid leukemia (CML), are at increased risk of …
(ET), polycythemia vera (PV), and chronic myeloid leukemia (CML), are at increased risk of …
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
N Gunnarsson, L Stenke, M Höglund… - British journal of …, 2015 - Wiley Online Library
Given that tyrosine kinase inhibitors (TKI s) have dramatically improved the survival of
patients with chronic myeloid leukaemia (CML), we were interested in examining the …
patients with chronic myeloid leukaemia (CML), we were interested in examining the …
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
MB Miranda, M Lauseker, MP Kraus, U Proetel… - Leukemia, 2016 - nature.com
Abstract Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the
introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent …
introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent …
Current therapy and new directions in the treatment of hairy cell leukemia: a review
A Sarvaria, Z Topp, A Saven - JAMA oncology, 2016 - jamanetwork.com
Hairy cell leukemia (HCL) is a chronic B-cell leukemia noted for an indolent course that
ultimately results in cytopenias and massive splenomegaly. Whereas treatment with the …
ultimately results in cytopenias and massive splenomegaly. Whereas treatment with the …
How I treat newly diagnosed chronic myeloid leukemia in 2015
C Gambacorti‐Passerini… - American journal of …, 2015 - Wiley Online Library
The initial treatment for chronic myeloid leukemia in chronic phase (CP‐CML) represents a
complex process, which includes a prompt and precise diagnosis, the choice among three …
complex process, which includes a prompt and precise diagnosis, the choice among three …
Temporal trends in the risk of developing multiple primary cancers: a systematic review
Background Cancer survivors are at risk of developing second and subsequent primary
cancers, referred to as multiple primary cancers (MPCs). It is not clear whether the risk of …
cancers, referred to as multiple primary cancers (MPCs). It is not clear whether the risk of …